The efficacy of regorafenib monotherapy as the third-and later-line treatment for metastatic colorectal cancer: a retrospective study
[Objectives] To investigate the efficacy and safety of regorafenib monotherapy as the third-and later-line treatment for metastatic colorectal cancer. [Methods] This was a retrospective analysis of 32 patients with metastatic colorectal cancer receiving regorafenib monotherapy as the third-and later...
Saved in:
| Main Authors: | An Tianqi, Song Lijie, Zong Hong, Zhao Ruihua |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Colorectal & Anal Surgery
2022-08-01
|
| Series: | 结直肠肛门外科 |
| Subjects: | |
| Online Access: | https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=377&cateName=2022%E5%B9%B4%20%E7%AC%AC28%E5%8D%B7%20%E7%AC%AC4%E6%9C%9F |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01) -
METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01) -
Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)
by: Tanios Bekaii-Saab, et al.
Published: (2025-06-01) -
The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies
by: Fan Yang, et al.
Published: (2025-05-01) -
Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review
by: Abdullah Esmail, et al.
Published: (2025-04-01)